| Common Brands | Balversa |
|---|---|
|
Drug Class |
Fibroblast growth factor receptor (FGFR) inhibitor |
|
Controlled Substance Classification |
Not a controlled medication |
|
Generic Status |
No Lower-cost generic available |
|
Availability |
Prescription only |
Balversa is an oral prescription drug that contains the active ingredient erdafitinib. It is primarily used for the treatment of bladder cancer, specifically metastatic urothelial carcinoma (mUC), which is a type of bladder cancer that has spread to other parts of the body. Balversa is a targeted therapy that inhibits specific proteins contributing to cancer cell growth and is used in patients whose cancer has specific genetic alterations (FGFR mutations).
Balversa received approval from the FDA of the United States in 2019 to treat patients with locally advanced or metastatic urothelial carcinoma who harbor alterations in the FGFR2 or FGFR3 genes and whose disease has progressed during or after any number of lines of prior chemotherapy, including platinum-containing chemotherapy. It is a drug class of FGFR inhibitors.
Balversa is administered orally in the form of tablets and is usually taken once a day. The doctor determines the dose based on the patient’s response and tolerability, but the usual recommended dose is 8 mg daily for most patients. The dose may be reduced based on side effects or specific medical considerations.
Administration: Balversa should be administered with or without food. Tablets should be swallowed intact with water.
Missed Dose: If one misses a dose, one should take it as soon as possible unless it is close to the time for his next dose. One should not take two doses at once in order to make up for a missed dose.
Dosage Adjustments: Dosages may be titrated up or down depending on side effects, like elevated phosphate levels, that cannot be tolerated.
Balversa (erdafitinib) is a drug that inhibits the activity of the fibroblast growth factor receptor. FGFRs are proteins located on the cell surface that are critical to regulate normal cell functions such as proliferation, survival, and differentiation. In some cancers, mutations or amplifications of FGFR2 and FGFR3 can result in excessive or unregulated activation of these receptors and hence lead to uncontrolled cancer cell growth.
The medication Erdafitinib selectively binds to these mutated FGFRs and inhibits the tyrosine kinase activity that is crucial for downstream signaling leading to the proliferation and spread of cancer cells. Through this pathway, Balversa may reduce cancer cell growth, especially metastatic urothelial carcinoma patients with genetic alterations in the FGFR.
Unlike any drug, Balversa can cause side effects; the most common of them are:
Eye problems: Balversa can lead to ocular problems, which include distorted vision, dry eyes, and retinal changes causing loss of vision. This requires regular vision monitoring on the patient’s part.
High phosphate levels: Hyperphosphatemia is a side effect that can lead to raised phosphate levels in the body. This is usually accompanied by symptoms such as muscle spasm, joint pain, and itching. Regular monitoring for phosphate levels in the patients is essential.
Fatigue: Some patients may experience feelings of tiredness or weakness.
Diarrhea: Gastrointestinal side effects such as diarrhea are common.
Nausea: Some patients may feel nauseous or experience vomiting during treatment.
Eye Toxicity: Balversa has been associated with eye problems, including retinal damage. Regular eye exams are essential during treatment. If patients experience vision changes, they should report it immediately to their doctor.
Hyperphosphatemia: Elevated phosphate levels are common, and patients must have their phosphate levels monitored regularly. High phosphate levels can lead to symptoms such as joint pain, muscle spasms, and itching.
Liver Function: Liver function should be monitored in patients with Balversa use since liver enzymes are influenced by it.
Pregnancy Category D: As it falls under the medication that might cause harm to the developing fetus, it shouldn’t be used during pregnancy unless in cases where the use would compensate for the risk posed. Also, it’s not established whether Balversa crosses to breast milk hence it should be avoided especially in the breastfeeding mother.
Drug Interactions: Concomitant use of Balversa with other drugs or with strong inhibitors or inducers of liver enzymes including CYP3A4 may lead to drug-interacting effects. Patients should let their healthcare provider know regarding all other medications they are using.
CYP3A4 Inhibitors: Using Balversa with strong CYP3A4 inhibitors (like ketoconazole or itraconazole) may increase the concentration of Balversa in the blood, increasing the risk of side effects. Dose adjustments may be necessary.
CYP3A4 Inducers: Medications like rifampin or St. John’s Wort, which induce CYP3A4 enzymes, can decrease the effectiveness of Balversa by lowering its concentration in the bloodstream.
Anticancer Drugs: Combining Balversa with other anticancer treatments (like chemotherapy agents) may increase the risk of severe side effects, so close monitoring is needed.
P-glycoprotein Substrates: Co-administration with drugs that are P-glycoprotein substrates (such as digoxin) may alter the absorption and effectiveness of either drug.
The standard starting dose for Balversa is 8 mg once daily. However, dosing can be adjusted as tolerated by the patient and as needed to achieve a sufficient response to the drug. In some cases, the dose may be reduced if side effects such as elevated phosphate levels or eye toxicity become severe.
If the phosphate level is too high, more than 7.5 mg/dL, the dose of Balversa can be reduced, or phosphate-lowering agents can be administered.
If there are severe side effects in the eyes, or other serious side effects, the treatment should either be stopped temporarily or, in some cases, not resumed.
Patients must always follow the advice of the doctor and report for subsequent follow-up visits to enable monitoring of side effects as well as adjustments in the regimen if necessary.
Balversa is a prescription drug, which means only a healthcare professional can prescribe it. Before initiating treatment, patients will be required to undergo genetic testing to verify that their bladder cancer contains appropriate FGFR2 or FGFR3 mutations that may respond to the treatment given by Balversa. The drug is usually prescribed by an oncologist with knowledge of the patient’s condition and treatment history.
What is Balversa?
Balversa is a prescription medication used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific mutations in the fibroblast growth factor receptor 1, 2, or 3 (FGFR1, FGFR2, or FGFR3).
What is the active ingredient in Balversa?
The active ingredient in Balversa is erdafitinib, which belongs to a class of drugs known as tyrosine kinase inhibitors.
How does Balversa work?
Balversa works by inhibiting the activity of the FGFR, which can help slow down or stop the growth of cancer cells that depend on these receptors.
Who is a candidate for Balversa treatment?
Candidates are adults diagnosed with NSCLC that has progressed after chemotherapy or targeted therapy and who have specific FGFR mutations.
What is the typical dosage of Balversa?
The typical starting dosage is 8 mg taken orally once daily, which may be adjusted based on tolerance and response.
How should Balversa be taken?
Balversa should be taken by mouth, with or without food, at the same time each day to maintain consistent levels of the medication in the body.
What are the common side effects of Balversa?
Common side effects include fatigue, diarrhea, dry mouth, and alterations in taste.
Are there serious side effects associated with Balversa?
Serious side effects can include hyperphosphatemia (high phosphorus levels), eye problems, and liver problems. Regular monitoring is essential.
Can Balversa cause vision changes?
Yes, Balversa can cause serious eye-related side effects, including blurred vision and dry eye. Patients should have regular eye examinations.
Is Balversa safe for pregnant or breastfeeding individuals?
No, Balversa is not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant.
Can Balversa interact with other medications?
Yes, Balversa may interact with other medications, so it’s important to inform your healthcare provider about all medicines you are taking.
How long can one expect to take Balversa?
The duration of treatment depends on individual response to the medication and the development of side effects, as determined by the healthcare provider.
Can Balversa be used in combination with chemotherapy?
Balversa is typically used as a standalone treatment but may be combined with other treatments based on the clinical scenario.
What should I do if I miss a dose of Balversa?
If you miss a dose, take it as soon as you remember on the same day. If it’s almost time for your next dose, skip the missed dose and resume your regular schedule.
What monitoring is required during treatment with Balversa?
Regular blood tests to check phosphorus levels, liver function, and eye examinations are recommended during treatment.
Are there any dietary restrictions while taking Balversa?
Patients should consult their healthcare provider regarding any dietary restrictions, especially related to phosphorous intake.
How should Balversa be stored?
Balversa should be stored at room temperature, away from moisture and heat, and kept out of reach of children.
Is Balversa available in generic form?
As of now, Balversa is not available in generic form; it is marketed under the brand name only.
Where can I get Balversa?
Balversa is available through pharmacies with a valid prescription from a healthcare provider.
What should I do if I experience side effects while on Balversa?
If you experience side effects, report them to your healthcare provider, who can provide guidance on managing or mitigating these effects.
Seborrheic dermatitis is a widespread chronic inflammatory skin disorder that primarily affects the head, scalp, and upper trunk, which are areas rich in sebaceous glands. Despite not being a fatal illness, the chronic nature of the disorder and its frequent flare-ups can greatly lower the person’s standard of life. The goal of this thorough investigation
For a considerable time, both scientists and medical experts have been fascinated by the connection between the gastrointestinal tract and the brain. The gut-brain axis is a concept that has emerged from emerging research that highlights the deep relationship between both of these seemingly different organs. We will explore the elements, functions, and consequences associated
Food intolerances are becoming more widely acknowledged as serious health issues impacting people all over the world. In contrast to food allergies, which are immune system-related, food intolerances usually refer to the body’s incapacity to properly digest specific substances or dietary ingredients. This thorough review explores several kinds of food intolerances, such as fructose malabsorption,
